Loading...

IRON DISC MEDICINE INC Product Launches 8-K Filing

DSC

RN

DISC MEDICINE INC

(IRON)

2024 8-K

Show Summary

Summary

Financial Statements

Financial Statements

Financial Results

FDA Meeting Update

Operational Update

Conference Call

Stock Offering Agreement

Financial Results

Clinical Trial Update

Financial Results

Annual Meeting of Stockholders

Underwriting Agreement

Clinical Trial Updates

Financial Results Announcement

Product Launches

Financial Results Announcement

Appointment of CFO and COO

Phase 2 BEACON Study Data R...

Phase 1b/2 Study Results

Agreement with Jefferies LLC

Financial Results Announcement

ASH Annual Meeting and Expo...

Departure of CFO

Open Market Sale Agreement

Termination of Sales Agreement

Financial Results Announcement

Public Offering

Suspended Offering

Annual Meeting of Stockholders

Initial Data from Phase 2 T...

Earnings Reports

Resignation of Director

Financial Results and Corpo...

Securities Purchase Agreement

Sales Agreement with SVB Se...

Entry into a Material Defin...

External Links:

Disc Medicine, Inc. announced topline results from its Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP), including significant reductions in protoporphyrin IX (PPIX) levels and improvements in phototoxic reactions and patient global impression of change (PGIC).

AI Assistant

DISC MEDICINE INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.